Stockscreener 앱 받기
10.05
2.43%
-0.25
Prothena Corporation Plc 주식(PRTA)의 최신 뉴스
Tools to monitor Prothena Corporation plc recovery probabilityOptions Play & Long-Term Capital Growth Ideas - newser.com
Why Prothena Corporation plc stock is seen as undervaluedMarket Performance Report & Daily Stock Momentum Reports - newser.com
FY2029 EPS Estimates for Prothena Boosted by HC Wainwright - MarketBeat
Prothena Corporation plc stock volume spike explained2025 Top Decliners & Community Consensus Trade Signals - newser.com
What data driven models say about Prothena Corporation plc’s futureMarket Weekly Review & Low Drawdown Trading Techniques - newser.com
What analysts say about Prothena Corporation plc stockAnalyst Downgrades & Build Your Portfolio With Our Free Stock Scanner - earlytimes.in
Prothena stock price target raised to $20 from $14 at H.C. Wainwright - Investing.com Nigeria
Prothena Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Public Employees Retirement System of Ohio Invests $256,000 in Prothena Corporation plc $PRTA - Defense World
Prothena Corp (PRTA) Sees Raised Price Target by HC Wainwright & Co. | PRTA Stock News - GuruFocus
Is now a turning point for Prothena Corporation plcBull Run & Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-05 07:33:52 - newser.com
Leading vs lagging indicators on Prothena Corporation plc performance2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Evaluating Prothena Corporation plc with trendline analysisWeekly Trade Review & Daily Profit Maximizing Tips - newser.com
Published on: 2025-10-03 05:55:14 - newser.com
How moving averages guide Prothena Corporation plc tradingJuly 2025 Summary & Free Technical Confirmation Trade Alerts - newser.com
Prothena Corporation plc (NASDAQ:PRTA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986 - PharmiWeb.com
Prothena's partner Bristol Myers Squibb obtains fast track designation from US FDA for BMS-986446 for treatment of Alzheimer's disease - MarketScreener
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease - Business Wire
Hopeful Week For Insiders Who Bought US$2.75m Of Prothena Stock - 富途牛牛
Published on: 2025-09-30 03:25:21 - newser.com
Published on: 2025-09-29 17:23:52 - newser.com
5.74%
자본화:
|
볼륨(24시간):